XML 51 R39.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
Equity (Details)
$ / shares in Units, $ in Thousands, vaccine_dose in Millions, shares in Millions
Mar. 18, 2021
USD ($)
vaccine_dose
Mar. 31, 2024
USD ($)
$ / shares
Dec. 31, 2023
USD ($)
$ / shares
Dec. 31, 2022
USD ($)
Dec. 31, 2021
USD ($)
Mar. 01, 2021
$ / shares
shares
Subsidiary, Sale of Stock [Line Items]            
Convertible preferred stock, par value (in USD per share) | $ / shares   $ 0.01 $ 0.01      
Series B Preferred Stock            
Subsidiary, Sale of Stock [Line Items]            
Preferred stock issued | $   $ 1 $ 1   $ 5,000  
Preferred stock, outstanding | $       $ 4,100    
Series B Preferred Stock | Fair Value, Inputs, Level 3 | Discount Rate            
Subsidiary, Sale of Stock [Line Items]            
Preferred stock, measurement input         0.15  
Series B Preferred Stock | COVAXIN Preferred Stock Purchase Agreement            
Subsidiary, Sale of Stock [Line Items]            
Agreement to sell, number of shares issued in transaction (in shares) | shares           0.1
Convertible preferred stock, par value (in USD per share) | $ / shares           $ 0.01
Agreement to sell, price per share (in USD per share) | $ / shares           $ 109.60
Advance payment amount | $ $ 6,000          
Conversion ratio (in shares)           10
Supply agreement, number of doses | vaccine_dose 10.0